4 November 2026

AROA BIOSURGERY H1 FY27 RESULTS & INVESTOR EVENT

H1 FY27 Results Webinar

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, AROA' or the 'Company') is pleased to announce it will hold a webinar with CEO Brian Ward and CFO James Agnew on **Tuesday 24 November 2026, at 9 AM AEDT,** to discuss the Company's half year results.

Register to attend via the following link:

https://us02web.zoom.us/webinar/register/WN_2Hd69FHRRe6RTy50VW1JAw

Questions can be submitted in advance to investor@aroa.com or live during the event.

Sydney Investor event – in person attendance only

An investor event will be held in Sydney CBD on **Wednesday 25 November 2026, from 10 am to 12.30 pm, AEDT**.

The event will give investors an opportunity to hear directly from AROA's leadership team about the Company's commercial outlook, clinical evidence supporting AROA ECM™ technology, and growth opportunities.

Investor attendance is in person only, with some speakers presenting remotely.

Time (AEDT)	Session	Speakers
10 AM	Welcome	Brian Ward, Chief Executive Officer
1010	Commercial update	Michael Lynskey Chief Commercial Officer – presenting remotely
1030	Reimbursement outlook	Zack Bridges, Director of Market Access, presenting remotely
1045	TELA Bio update	Brian Ward & James Agnew, Chief Financial Officer
1130	Myriad & MASTRR registry	Dr Barnaby May, Chief Scientific Officer
12 PM	Q&A and closing remarks	Brian Ward

Please RSVP to investor@aroa.com at your earliest convenience. Capacity is limited, and advance registration is required. Venue details will be shared once registration is confirmed.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

AROA BIOSURGERY LIMITED
ARBN 638 867 473 NZCN 1980577
64 Richard Pearse Drive, Auckland 2022, New Zealand
AROA.COM

About Aroa Biosurgery:

investor@aroa.com

About AROA™
Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for every*body*'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix bioscaffold derived from ovine (sheep) forestomach. Over 7.5 million AROA devices have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELABio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com

Contact

investor@aroa.com